顺铂腹腔灌注联合注射用黄芪多糖在胃癌合并恶性腹腔积液患者中的治疗效果观察

贾铭丽; 金世柱; 韩明子

doi:10.3969/j.issn.1671-038X.2016.12.10

顺铂腹腔灌注联合注射用黄芪多糖在胃癌合并恶性腹腔积液患者中的治疗效果观察

- 哈尔滨医科大学附属第二医院消化内科, 黑龙江哈尔滨 150000

详细信息

作者简介:
贾铭丽,女,硕士研究生,主要从事消化内科临床研究

通讯作者: 金世柱,E-mail:shizhujin@126.com

中图分类号: R735.2

收稿日期: 2016-01-07

Effect of cisplatin peritoneal perfusion combined with astragalus polysaccharides injection for patients with gastric cancer and malignant ascites

- Department of Digestive, The Second Affiliated Hospital of Harbin Medical University, Harbin 150000, China

More Information

Corresponding author: JIN Shi-zhu, E-mail: shizhujin@126.com

Received Date: 07 January 2016

摘要

摘要: [目的]研究顺铂联合注射用黄芪多糖腹腔灌注治疗方案在胃癌合并恶性腹腔积液患者中的治疗效果。[方法]选择2012年2月~2014年2月在本院就诊的胃癌合并恶性腹腔积液患者170例,随机分为研究组与对照组。2组各85名患者,均采用常规顺铂腹腔灌注治疗方案,研究组同时联合使用注射用黄芪多糖治疗。比较2组患者治疗后治疗效果、化疗不良反应、外周血中免疫因子以及腹水中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)表达情况的差异。[结果]2组治疗后结果显示研究组腹水治疗疗效(P=0.006)、生存质量(P＜0.01)、外周血CD3⁺、CD4⁺(P＜0.01)均显著优于对照组;腹水中TNF-α、IL-6的表达较对照组降低明显(P＜0.05);消化道反应(P=0.017)、白细胞减少(P=0.023)、肝功能损害(P=0.028)的发生率也较对照组明显降低。[结论]对胃癌合并恶性腹腔积液患者行顺铂腹腔灌注联合注射用黄芪多糖方案治疗能显著抑制其炎症表达,降低毒副反应的发生,提高治疗效果。
- 注射用黄芪多糖 /
- 胃癌 /
- 恶性腹水 /
- 炎性因子
Abstract: [Objective]To study the effect of Cisplatin peritoneal perfusion combined with astragalus polysaccharides(APS)injection for patients with gastric cancer and malignant ascites.[Methods]170 patients with gastric cancer and malignant ascitespatients were collected in our hospital from February 2012 to February 2014 and randomly divided into two groups.Both patients received Cisplatin peritoneal perfusion,meanwhile,the study group received astragalus polysaccharides injection.The treatment effect,adverse drug reaction,immune factors in peripheral blood and the expression of IL-6 and TNF-α were compared in malignant ascites.[Results]The reasults of two groups after trearment showed that the study group has a significant increase of the malignant ascites effect(P=0.006),quality of life(P＜0.001),and the expression of CD3⁺,CD4⁺(P＜0.001)in peripheral blood.Meanwhile,the expression of IL-6, TNF-α(P＜0.05),the occurrence of gastrointestinal reaction(P=0.017),Leukopenia(P=0.023) and liver damage(P=0.028)were significantly decreased.[Conclusion]Cisplatin peritoneal perfusion combined with Astragalus polysaccharides injection can inhibit the inflammation expression,reduce the occurrence of adverse drug reaction and improve the clinical therapy effects in patients with gastric cancer and malignant ascites
- astragalus polysaccharides /
- gastric cancer /
- malignant ascites /
- inflammation factor

HTML全文

参考文献(19)

[1]	IMAMOTO H,OBA K,SAKAMOTO J,et al.Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions:a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer[J].Gastric Cancer,2011,14:81-90.
[2]	邹小农,孙喜斌,陈万青,等.2003-2007年中国胃癌发病与死亡情况分析[J].肿瘤,2012,32(2):109-114.
[3]	MOTOTSUGU K,MASAHIRO A.Recent Development of Gastric Cancer Prevention[J].Jap J Clin Oncol,2012,42:987-994.
[4]	朱小鹏,唐昃,杨利华,等.多西紫杉醇腹腔热灌注化疗治疗老年胃癌并恶性腹水的临床效果[J].疑难病杂志,2015,(5):487-490.
[5]	YAMAGUCHI H,KITAYAMA J,EMOTO S,et al.Cell-free and Concentrated Ascites Reinfusion Therapy(CART)for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1[J].EJSO-EUR J Surg Onc,2015,41:875-880.
[6]	陈卓,于卫江.注射用黄芪多糖对非小细胞肺癌放疗的作用及对机体免疫的影响[J].中国实验方剂学杂志,2013,19(6):309-313.
[7]	ASSOCIATION J G C.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2011,14:113-123.
[8]	王志明,庄荣源,陈勇,等.化疗联合腹腔灌注细胞因子诱导的杀伤细胞治疗胃癌腹水[J].中华胃肠外科杂志,2013,16(1):28-31.
[9]	THOMAIDIS T,WORNS M A,GALLE P R,et al.Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma-a Report of 2Cases[J].Oncologie,2014,37:674-677.
[10]	常帅,车向明,陈锐,等.炎症细胞因子在胃癌进展中的作用[J].中国现代普通外科进展,2012,15(12):968-972.
[11]	LANDSKRON J,HELLANDØ,TORGERSEN K M,et al.Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients[J].Cancer Immunol Immun,2014,64:337-347.
[12]	ZELOVAH,HOSEK J.TNF-αsignalling and inflammation:Interactions between old acquaintances[J].Inflamm Res,2013,62:641-651.
[13]	梁翙,丁健民,刘小宇,等.TNF-α与IL-1β对胃癌腹膜间皮细胞黏附分子mRNA表达的影响[J].胃肠病学和肝病学杂志,2014,23(3):252-255.
[14]	JUN S,YI Z,JINHONG H.Curcumin Inhibits Imiquimod-Induced Psoriasis-Like Inflammation by Inhibiting IL-1beta and IL-6Production in Mice.[J].Plos One,2013,8:e67078-e67078.
[15]	杜义安,郭剑民.相关炎性因子在胃癌进展中的研究进展[J].中国肿瘤,2014,23(5):399-402.
[16]	TANIGUCHI K,KARIN M.IL-6and related cytokines as the critical lynchpins between inflammation and cancer[J].Semi Immunol,2014,26:54-74.
[17]	师金凤,李海龙,王红蕾,等.黄芪及其有效成分防治消化道肿瘤的文献评价[J].西部中医药,2014,(8):44-46.
[18]	成军,王锡英.黄芪多糖在晚期胃癌新辅助化疗中的作用[J].中国中西医结合外科杂志,2013,(5):542-543.
[19]	刘树勋,陈明聪,江辉斌,等.注射用黄芪多糖联合EOF方案治疗晚期胃癌疗效分析[J].中国中西医结合消化杂志,2014,22(11):684-686.